• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMylan

Mylan’s Blogger Recruits May Have Been ‘Buttered Up’ to Help Pass Bills

By
Reuters
Reuters
and
Michelle Toh
Michelle Toh
Down Arrow Button Icon
By
Reuters
Reuters
and
Michelle Toh
Michelle Toh
Down Arrow Button Icon
September 23, 2016, 4:03 AM ET
A file photo showing the EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company are seen in Washington
FILE PHOTO -- EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S. August 24, 2016. REUTERS/Jim Bourg/File Photo - RTX2NGZWPhotograph by Jim Bourg — Reuters

When Mylan recruited food allergy bloggers to learn about its campaign to get allergic shock antidotes into schools, many were eager to join the maker of the EpiPens they carry in purses and stash in book bags to protect their children against potentially lethal attacks.

The bloggers, more than a dozen mothers of children with serious allergies, embraced the effort Mylan (MYL) outlined in a series of “summits” it held for them beginning in 2013.

They wrote impassioned posts on blogs shared with tens of thousands of followers on social media. Their personal testimony helped persuade a number of state lawmakers to pass bills to get schools to stock epinephrine injectors, such as the EpiPen, according to legislators and others familiar with the lobbying effort.

During the same period, the company was marking up its EpiPen to more than $600 per twin pack, six times the 2007 price, creating a burden for many of the bloggers’ followers, other parents of children whose lives are threatened by bee stings and peanuts.

At least four of the bloggers told Reuters they believe Mylan took advantage of their goodwill. Some have joined public criticism of those price hikes.

“I personally believe that Mylan held the summits to gain blogger trust and then used those bloggers to spread word about their initiatives. They raised prices while those initiatives gained traction,” Ruth LovettSmith, a former food-allergy blogger from Massachusetts who attended three summits, said in an email.

Mylan spokeswoman Lauren Kashtan declined to comment on the criticism.

But in an email, she said the company regretted that it had not anticipated “the potential financial issues for the growing minority of patients” whose EpiPens are not covered by insurance or a patient assistance program.

Mylan now offers coupons to more families to cover out-of-pocket costs and said it would soon release a half-price EpiPen.

Kashtan also said the blogger summits served a worthy purpose.

“Mylan aimed to provide access to information, resources and expertise about anaphylaxis and life-threatening allergies,” said Kashtan, who represented the company at four summits. “We are proud to have brought together such a passionate and dedicated group of advocates.”

Chief executive Heather Bresch was blasted Wednesday at a hearing before U.S. lawmakers who, along with prosecutors in several states, are investigating the price hikes.

EpiPen sales exceed $1 billion a year and command more than 90% of the market.

See also: Don’t Only Blame Mylan for $600 EpiPens

STEAKS AND BLOG POLISHING

The effort to get epinephrine injectors into schools is a point of pride for Mylan, which has credited its alliances with advocates for its success.

“We have collaborated with government officials, leading advocacy organizations, parents, caregivers and healthcare professionals to successfully champion legislation and policies,” Mylansaid in a 2015 report on its social responsibility efforts.

LovettSmith, whose son has nut allergies, went to her first Mylan blogger summit in January 2013 at a boutique midtown Manhattan hotel overlooking the Empire State Building.

It was the first of at least four summits, each involving about 15 bloggers, some of whom attended more than one event. They wrote about being treated to three-course dinners featuring pan-seared yellow fin tuna or marinated grilled hanger steak.

At a 2014 summit at the company’s Canonsburg, Pa., headquarters, Mylan brought an outside communications consultant to help the women polish their blogs, advocate to policymakers, practice on-camera television interviews and speak at public events, participants told Reuters.

Homa Woodrum, a lawyer in Las Vegas whose 8-year-old daughter relies on EpiPens for nut and oat allergies, attended that summit. But she skipped an invitation to a May 2015 event at California’s Disneyland, uncomfortable with the shift in venue to a resort.

“It starts to seem a little like you’re being buttered up,” Woodrum said.

Bloggers who attended summits testified on behalf of schools’ bills in Nevada, Maine and Michigan, according to interviews and legislative records. In all, 48 states adopted laws requiring or enabling schools to stock epinephrine injectors. In many cases, Mylan subsequently donated EpiPens to schools.

Stanley Short, a Democratic representative who co-sponsored the Maine bill, credited a blogger with alerting him to the issue. The woman, who attended the Disneyland summit, brought her son to a legislative hearing, where he demonstrated how he would press an EpiPen into his thigh to stop an allergic reaction.

Mylan‘s lobbyist attended the hearing, but the boy’s show-and-tell “sealed the deal,” Short said. “With me and most of the legislators, it’s that first-hand experience of a mother talking about her child and a child talking about what they go through personally that did it.”

See also: Mylan’s CEO Tells Congress the EpiPen Price Hike Was ‘Fair’

MIXED REACTIONS

Bloggers who went to Disneyland told Reuters pricing was not on the drugmaker’s agenda. By then, some were aware of the hikes and brought them up. Mylan talked about the role of other parties, including insurers, in determining what consumers pay, they said.

Blogger Kelly Rudnicki’s food allergy advocacy led to work as a paid Mylan spokeswoman. But, she said in an email, she quit last month because of the pricing controversy. She said she believes Mylan should apologize and cut its prices on EpiPens, and Bresch should step down.

Rudnicki, whose 14-year-old son has severe food allergies, said the bloggers supported Mylanbecause they believed it “had our back and manufactured a device that we couldn’t live without.”

Mylan declined to discuss Rudnicki’s criticism. The company confirmed she resigned, adding it had thanked her for her work.

Some bloggers like Caroline Moassessi, a food allergy activist from Reno, Nev., take a more nuanced view.

She attended three summits and testified in Nevada to allow schools and other public venues to stock epinephrine.

She also has felt the full effect of price hikes. As a small business owner, she paid $3,000 in 2015 for EpiPens for her son and daughter. Each child carries two pens at all times and keeps two more at school. Moassessi also carries two injectors.

While Moassessi would rather pay less, she said she recognizes that Mylan is in business to make a profit.

“I know they’re a business trying to make as much as they can, like Ford, Chevy, Macy’s,” she said. “I’m not naive about that, whatsoever.”

About the Authors
By Reuters
See full bioRight Arrow Button Icon
By Michelle Toh
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Latest in Health

FDA
HealthDrugs
Female libido pill gets expanded approval for menopause by FDA
By Matthew Perrone and The Associated PressDecember 15, 2025
20 hours ago
HealthCommentary
Nicotine pouches offer huge promise—so long as the U.S. doesn’t repeat its mistake with vaping
By Max CunninghamDecember 14, 2025
2 days ago
Thompson
C-SuiteMedia
Atlantic CEO Nick Thompson on how he learned to ‘just keep moving forward’ after his famous firing at 22
By Nick LichtenbergDecember 14, 2025
2 days ago
HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
3 days ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
3 days ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
3 days ago

Most Popular

placeholder alt text
Success
'I had to take 60 meetings': Jeff Bezos says 'the hardest thing I've ever done' was raising the first million dollars of seed capital for Amazon
By Dave SmithDecember 15, 2025
1 day ago
placeholder alt text
Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action, by blocking his calendar every afternoon from Wednesday to Friday 
By Preston ForeDecember 15, 2025
1 day ago
placeholder alt text
Success
Bad luck, six-figure earners: Elon Musk warns that money will 'disappear' in the future as AI makes work (and salaries) irrelevant
By Orianna Rosa RoyleDecember 15, 2025
1 day ago
placeholder alt text
Personal Finance
Current price of silver as of Monday, December 15, 2025
By Joseph HostetlerDecember 15, 2025
1 day ago
placeholder alt text
North America
Ford writes down $19.5 billion as it pivots electric Lighting line of vehicles
By Sasha RogelbergDecember 15, 2025
21 hours ago
placeholder alt text
AI
Deloitte's CTO on a stunning AI transformation stat: Companies are spending 93% on tech and only 7% on people
By Nick LichtenbergDecember 15, 2025
1 day ago